[go: up one dir, main page]

SI2723176T1 - Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala - Google Patents

Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala

Info

Publication number
SI2723176T1
SI2723176T1 SI201231012T SI201231012T SI2723176T1 SI 2723176 T1 SI2723176 T1 SI 2723176T1 SI 201231012 T SI201231012 T SI 201231012T SI 201231012 T SI201231012 T SI 201231012T SI 2723176 T1 SI2723176 T1 SI 2723176T1
Authority
SI
Slovenia
Prior art keywords
chemically
sodium channel
channel blocker
metabolically stable
blocker activity
Prior art date
Application number
SI201231012T
Other languages
English (en)
Inventor
Michael Ross Johnson
Original Assignee
Parion Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parion Sciences, Inc. filed Critical Parion Sciences, Inc.
Publication of SI2723176T1 publication Critical patent/SI2723176T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/30Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
    • C07D241/32(Amino-pyrazinoyl) guanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SI201231012T 2011-06-27 2012-06-27 Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala SI2723176T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501524P 2011-06-27 2011-06-27
EP12803924.5A EP2723176B1 (en) 2011-06-27 2012-06-27 A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
PCT/US2012/044372 WO2013003444A1 (en) 2011-06-27 2012-06-27 A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity

Publications (1)

Publication Number Publication Date
SI2723176T1 true SI2723176T1 (sl) 2017-09-29

Family

ID=47424521

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231012T SI2723176T1 (sl) 2011-06-27 2012-06-27 Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala

Country Status (13)

Country Link
US (4) US9072738B2 (sl)
EP (1) EP2723176B1 (sl)
CN (1) CN103687488B (sl)
BR (1) BR112013032771B1 (sl)
CA (1) CA2839709C (sl)
DK (1) DK2723176T3 (sl)
ES (1) ES2633177T3 (sl)
HR (1) HRP20171044T1 (sl)
HU (1) HUE032851T2 (sl)
PL (1) PL2723176T3 (sl)
PT (1) PT2723176T (sl)
SI (1) SI2723176T1 (sl)
WO (1) WO2013003444A1 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
SI2723176T1 (sl) 2011-06-27 2017-09-29 Parion Sciences, Inc. Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala
WO2013064451A1 (en) 2011-11-02 2013-05-10 Boehringer Ingelheim International Gmbh Novel process for the preparation of acylguanidines and acylthioureas
KR102006612B1 (ko) 2011-11-02 2019-08-02 베링거 인겔하임 인터내셔날 게엠베하 헤테로사이클릭 화합물, 상기 화합물을 포함하는 약제, 이의 용도, 및 이의 제조 방법
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
EP2861577B1 (en) 2012-05-25 2017-01-04 Boehringer Ingelheim International GmbH Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof
LT2855435T (lt) 2012-05-29 2018-09-10 Parion Sciences, Inc. Amino amidai, panašūs į dendrimerus, su natrio kanalų blokavimo aktyvumu, skirti gydyti sausų akių sindromą ir kitas gleivinių ligas
EP2897940B1 (en) 2012-09-24 2019-05-01 Boehringer Ingelheim International GmbH Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
WO2014099673A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
KR20160045863A (ko) 2013-08-23 2016-04-27 패리온 사이언스 인코퍼레이티드 디티올 점액 용해제
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers
CN112321472A (zh) 2015-01-30 2021-02-05 帕里昂科学公司 新型单硫醇粘液溶解剂
JP2018520986A (ja) 2015-04-30 2018-08-02 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解剤の新規なプロドラッグ

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299931A (sl) 1962-10-30
JPS6034925B2 (ja) 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4479932A (en) 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS6032714A (ja) 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5492112A (en) 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
EP0940154B1 (en) 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
RO113214B1 (ro) 1992-10-19 1998-05-29 Dura Pharma Inc Inhalator de pulbere uscata
US5819726A (en) 1993-01-29 1998-10-13 Aradigm Corporation Method for the delivery of aerosolized drugs to the lung for the treatment of respiratory disease
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US6264975B1 (en) 1998-10-20 2001-07-24 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
EP1670474A4 (en) 2003-08-18 2008-08-06 Parion Sciences Inc BLOCKERS OF THE PYRAZINOYL-GUANIDINE SODIUM CHANNEL
CA2534568A1 (en) 2003-08-18 2005-03-24 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers
CA2534682C (en) 2003-08-18 2013-02-26 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
JP2008510708A (ja) 2004-08-18 2008-04-10 マイケル・アール・ジョンソン 環式アミド及びエステルピラジノイルグアニジンナトリウムチャネル遮断薬
EP1786427A4 (en) 2004-08-18 2009-11-11 Michael R Johnson BLOCKERS OF SODIUM CHANNELS OF PYRAZINOYLGUANIDINE WITH AMIDE AND ALIPHATIC ESTER
US20090324724A1 (en) 2004-08-18 2009-12-31 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
DK2035004T3 (en) * 2006-06-09 2013-01-02 Parion Sciences Inc Phenylsubstituerede pyrazinoylguanidin-natriumkanalblokkere med beta-agonistaktivitet
US20110195973A1 (en) 2006-06-09 2011-08-11 Parion Sciences, Inc. Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
WO2007146867A2 (en) 2006-06-09 2007-12-21 Parion Sciences Inc. Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
MX2009002602A (es) 2006-09-07 2009-05-28 Parion Sciences Inc Metodos para aumentar la hidratacion mucosa y el despeje mucoso mediante tratamiento con bloqueadores de canal de sodio y osmolitos.
AR062742A1 (es) 2006-09-07 2008-12-03 Johnson Michael R Hidratacion de la mucosa y depuracion de la mucosa aumentadas por tratamiento con bloquadores de canales de sodio y osmolitos
WO2008124491A1 (en) 2007-04-03 2008-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use taste modulators
WO2008124496A1 (en) 2007-04-03 2008-10-16 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough, and central nervous system disorders
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
TWI432198B (zh) 2008-02-26 2014-04-01 Parion Sciences Inc 多芳香族鈉通道阻斷劑
US20100074881A1 (en) 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
SI2723176T1 (sl) 2011-06-27 2017-09-29 Parion Sciences, Inc. Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
LT2855435T (lt) 2012-05-29 2018-09-10 Parion Sciences, Inc. Amino amidai, panašūs į dendrimerus, su natrio kanalų blokavimo aktyvumu, skirti gydyti sausų akių sindromą ir kitas gleivinių ligas
WO2014099673A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity

Also Published As

Publication number Publication date
US9072738B2 (en) 2015-07-07
CN103687488A (zh) 2014-03-26
CN103687488B (zh) 2015-06-10
EP2723176B1 (en) 2017-04-12
HUE032851T2 (en) 2017-11-28
DK2723176T3 (en) 2017-07-31
US9655896B2 (en) 2017-05-23
CA2839709C (en) 2020-01-14
BR112013032771A2 (pt) 2016-08-16
WO2013003444A1 (en) 2013-01-03
CA2839709A1 (en) 2013-01-03
PL2723176T3 (pl) 2018-01-31
HRP20171044T1 (hr) 2017-10-06
US20170281620A1 (en) 2017-10-05
US10159672B2 (en) 2018-12-25
US20180104241A1 (en) 2018-04-19
BR112013032771B1 (pt) 2021-01-12
US20140142118A1 (en) 2014-05-22
EP2723176A4 (en) 2014-11-12
PT2723176T (pt) 2017-07-18
ES2633177T3 (es) 2017-09-19
EP2723176A1 (en) 2014-04-30
US20150290189A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
SI2723176T1 (sl) Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala
SG11201401068SA (en) Device communication using a reduced channel bandwidth
EP2702551A4 (en) SELECTIVE DIGITAL SERVICE FEEDS WITH SEVERAL CAROUSELS
HRP20171389T1 (hr) Pirimidini kao blokatori natrijevog kanala
IL227346A0 (en) Anti-diabetic agent to reduce fats
GB2492051B (en) Channel bandwidth
GB201118728D0 (en) Smokeable material recovery
EP2692099A4 (en) FLEXIBLE PREEMPTION TO MAKE MINIMUM PREEMPTIONS IN A NETWORK
ZA201307752B (en) Self-lighting device for a cigarette
PL2744832T3 (pl) Macierze zawierające zmodyfikowany polisacharyd
ZA201306985B (en) A sunscreen composition
PL2476859T3 (pl) Urządzenie do zacieniania
AU334198S (en) A channel
ZA201307751B (en) Cigarette provided with a self-lighting device
PL2514902T3 (pl) Taśma uszczelniająca
GB2488627B (en) A sealing strip
PL2584110T3 (pl) Taśma uszczelniająca
PH32011000484S1 (en) Handset
PH32011000324S1 (en) Cigarette packet
PH32011000325S1 (en) Cigarette packet
PH32011000326S1 (en) Cigarette packet
PH32011000327S1 (en) Cigarette packet
PH32011000328S1 (en) Cigarette packet
AU2011900750A0 (en) A Smoking Device
GB201107196D0 (en) Common channel configuration for multipoint communications